A MOST CHALLENGING YEAR

In 2020, the pandemic challenged the lung cancer community and patients everywhere.

There were many concerns: the uncertainly around COVID-19 and lung cancer, limited access to care and preventive screenings, and feelings of isolation away from loved ones. Despite these challenges, our community persevered and, thanks to you, our most ardent supporters, GO2 Foundation was there to meet the increased demand for information and supportive services and continued to expand our programs. We are proud to share a few examples of 2020 progress:

- Provided weekly and sometimes daily information about COVID and lung cancer.
- Launched new programs for our most high-risk and vulnerable communities, including a partnership with the Department of Veteran Affairs to advance life-saving early detection.
- Improved access to higher quality and more personalized care in communities across the country through our growing Centers of Excellence network of healthcare facilities.
- Conducted innovative research in collaboration with our research partner, the Addario Lung Cancer Medical Institute.

We are stronger together. By the end of 2020, your donations totaled more than $14 million. This funding ensured support for patients and families through information, education, support, advocacy, and research. In addition to exceeding our revenue goals, we welcomed more new participants than ever before via our virtual events and engaged all 50 states in our Shine A Light on Lung Cancer program hosted virtually in hospital settings nationwide during Lung Cancer Awareness Month. We are pleased to have provided hope and support during this unprecedented year.

In this Annual Report, we share some of the remarkable community stories made in response to and despite the pandemic. Throughout the year, we connected thousands of people all across the country to help us “empower everyone, and ignore no one” and it is their stories that continue to motivate us now and into the future.

Thanks to your generosity, we were able to sustain our mission and vital services when our community needed us the most. We will continue to innovate and effectively guide programs to meet our vision of doubling survival rates from 20% to 40% by 2025.

On behalf of the millions living with and at risk for the disease, thank you for making our work possible.

Sincerely,

Bonnie J. Addario
Co-Founder, Board Chair

Laurie Fenton Ambrose
Co-Founder, President & CEO
The Impact of Lung Cancer Across Generations: One Family’s Story

Lung cancer doesn’t just impact one person—it affects all those who love them.

Perhaps no family understands this better than the Jain-Patkar family. Meet Usha Jain, a retired professor in the Department of South and Southeast Asian Studies at UC Berkeley and the author of the definitive textbooks for teaching Hindi. During a trip to Spain in July 2018 she started suddenly coughing in a concerning and uncontrolled way. She came home and was diagnosed with Stage IV lung cancer. Two years of chemotherapy followed. “I tolerated the treatments quite well,” says Usha Jain. “My family and friends were amazed that I had only a few side effects from the chemotherapy.”

And meet Usha’s daughter, Amita Jain, a pediatrician in the San Francisco Bay area. Six months after her mother’s diagnosis, Amita was experiencing subtle neurological symptoms—enough to worry her family. She had an MRI in January 2019 and was diagnosed with Stage IV lung cancer. Like her mother, she’d never smoked. “I am lucky to have an ALK mutation,” says Amita Jain. “Because of research, I’m on a medication that did not exist five years ago.”

Now Usha worries about her daughter, and Amita worries about her mother. And they both worry about what it means for the next generation. “We used to go to the in-person Living Rooms, and we would always ask about our children,” says Amita. “They don’t think it’s genetic because we have different versions. But it’s an unknown.”

That next generation includes Neha Patkar, Usha’s granddaughter and Amita’s daughter, a sophomore at Stanford University. Neha is studying human biology and Spanish, and she shared that she’s interested in learning more about how environmental factors impact people’s health. “Living in the Bay Area two months of the year we have horrible air quality and can’t go outside,” says Neha Patkar. “This obviously impacts lung health.”

Finding a community at GO2 Foundation

It was Neha Patkar who first found GO2 Foundation as she was searching for information and support for her mother and grandmother. She and her parents started attending the monthly Lung Cancer Living Room, tuning in from home since the event’s shifted to virtual-only during the COVID-19 pandemic. “For my mom and my grandma, it was a place of support, and a strong community that we wanted to be a part of,” says Neha. Her mother agrees, saying it was empowering to be in a room with other patients.

Neha also signed herself and her mom up for the Virtual Lung Cancer Voices Summit in March. During congressional meetings, her mother told lawmakers, “I am sitting here today speaking to you because of the medications and innovations that have come out of lung cancer research. We need to continue funding this research to make life-changing and life-saving discoveries.”

Neha, meanwhile, says listening to her mother and others with lung cancer reminded her that “doing something as simple as sharing our story can have a profound impact.” Neha Patkar says the other big takeaway from the Voices Summit was learning more about women and lung cancer. “I learned a lot of statistics that are staggering,” she says, “and especially the young women who are getting lung cancer. It’s a little jarring for me.”

To learn more about women and lung cancer and take action go to https://go2foundation.org/advocacy/policy-priorities/women-and-lung-cancer-research-and-preventive-services-act/.
Doubling Down on Cancer Survival

Over the next five years, GO2 Foundation’s goal is to double survival rates from 20% to 40%. Ten years ago, this goal would be dismissed as impossible. Today, it’s achievable. Accelerating change across the entire continuum of care — from risk assessment and early diagnosis to treatment research and long-term survivorship — is our roadmap for success. Because the majority of healthcare is delivered at the community level, we need to act locally and inform globally to effectively bring the full potential of recent advances to patients.

Moving forward, we will focus on:

- Increasing the rate of lung cancers diagnosed early.
- Increasing the rate of comprehensive biomarker testing and use of precision medicine.
- Increasing the reach and the impact of community engagement.
- Improving quality of life for patients diagnosed with lung cancer.
COVID-19—Transforming to Meet Community Needs

In March 2020, GO2 Foundation transformed to meet community needs for information and guidance on COVID-19.

- 90,000 community members in 36 countries watched our COVID-19 Rapid Response Lung Cancer Living Room episodes.
- 25+ policy letters sent to Congress to continue advocacy for funding, treatment, and care.
- 300+ healthcare workers attended special COVID-19 webinars and peer-to-peer learning.
- 4 separate research studies established on the impact of COVID-19 on the lung cancer community.
- 13,000 people visited the COVID-19 and Lung Cancer section of our website.
- 186 social media posts on COVID-19 with 24,000 engagements.
- 500+ participants at the online only Virtual Summer Jam 5K Your Way.

“Hope. We met and are now seeing a way past an incredibly difficult year of our lives.”

Laurie Fenton Ambrose,
Co-Founder, President, and CEO
Reaching High-Risk and Vulnerable Communities

We proudly partnered with the U.S. Department of Veteran Affairs (VA) to expand our reach into the Veteran community to improve outcomes and save lives. Through this partnership health care professionals and the broader lung cancer community received educational resources to increase awareness of the unique risk factors, needs, and concerns of Veterans, along with information on the importance of screening and early detection.

“As a retired soldier, it wasn’t until I joined the Board of GO2 Foundation that I became aware of our elevated risk for the disease. I encourage you to get the facts about lung cancer screening and access the professional and caring HelpLine staff to answer questions and refer you to responsible screening and care near you.”

Rick Sherlock, GO2 Foundation Board Member and Major General, United States Army, Retired
Improving Access to Care

GO2 Foundation’s Centers of Excellence (COE) network comprises 800+ primarily community-based medical facilities committed to best practices while serving tens of thousands of patients across the country. Expanding and maximizing this network enabled GO2 Foundation to directly reach patients, healthcare providers, and the broader community to improve survival on a national scale.

800+
Centers of Excellence

51%
Diagnosed through early detection at Stage I versus the 16% national average.

81%
Comprehensive molecular testing rates and clinical trial option reviews.

100%
Multi-disciplinary teams, including specialists in pathology, social work, and clinical research.
Conducting Innovative Research

Working with our research partner, the Addario Lung Cancer Medical Institute (ALCMI), and our Lung Cancer Registry, we conducted research studies, drove patient participation, and identified critical gaps where scientific exploration may contribute to cures.

Click here to read about all of our studies.

**Epidemiology of Young Lung Cancer**
What are the risks factors for lung cancer in patients under 40?

**SPACEWALK**
How ALK+ lung cancer evolves.

**Genomics of Young Lung Cancer**
Why lung cancer looks different in people under age 40.

**SHAWL**
Sexual Health Assessment in Women with Lung Cancer.
Engaging the Lung Cancer Community

GO2 Foundation’s core priority is to serve patients and ensure that no one is alone managing a diagnosis, understanding treatment options, and benefiting from screening. Lung cancer is a survivable disease — with more options than ever before to extend and save lives.

Connections
- 200,000 community members.
- 100,000 followers on social media.

Support
- 3,842 supportive conversations through our HelpLine, LungMATCH, and Phone Buddy services.

Advocacy
- 320 advocates representing 34 states in 160 different meetings with House Representatives and Senators.

Participation
- 3,000 participants, raising $1.5 million at fundraising 5Ks, marathons, DIYs, and the GALA.
- 9,919 individual gifts and grants to support GO2 Foundation initiatives.
Your Contributions at Work

Over 80% of every dollar donated advanced our Patient & Support Services, Science & Research, Excellence in Screening & Care, Government Affairs & Health Policy, Education & Awareness, and Community Engagement programs.

See how your dollars were put to work in fiscal year 2020 (January 1 – December 31).

Our Board of Directors is composed of volunteer leaders committed to helping the organization raise awareness for lung cancer, lower stigma, and increase survivorship. We are incredibly grateful for their thoughtful and guiding service to this community.

Lisa Poulin, Member of the Board of Directors

“I continue to be amazed by the team at GO2 Foundation. Despite the many challenges facing the lung cancer community during the COVID pandemic, they rose to the occasion by quickly adjusting programs and ensuring that everyone who reached out to us had the most up-to-date information and compassionate support. Innovative research, women and lung cancer advocacy, and early detection efforts particularly for the underserved continued full speed ahead. I’m honored to serve as a board member and thank our many donors who generously stepped up and made this work possible during an unprecedented year.”

Lisa Poulin, Member of the Board of Directors
Supporters

Thank you to each of our donors for your life-saving support. We are proud to recognize the following individuals whose generosity exceeded $2,500.

Anonymous
Stian Agnes
Tony and Bonnie J. Addario
Amgen
Ann and Charles Florsheim Family Foundation
Anonymous
Apollonics, Inc.
AstraZeneca
Valerie L. Atikian
Ann and Charles Florsheim Family Foundation
Anonymous
Jennifer Boyles
&
Janet Bain
she Brown Foundation
&
Timothy & Melissa Draper
Dreams33 Foundation
The Gordon T. and Melissa A. Egan Family Foundation
Elevation Oncology
Elu Lilly and Company
Ross Ellis
EMD Serono
The Gordon T. and Melissa A. Egan Family Foundation
Gale & Linda England
EQRx
Clark & Ellen Evans
Event Strategy Group
Every Breath Counts Foundation
David Feldman
Kenneth and Leah Fine
The Fitzpatrick Foundation
Patricia W. Fitzpatrick Fund
Memorial Cancer Specialists and Research Institute
Florida Farm Bureau Casualty Insurance Company
Ronne & Frances Fang Foundation Medicine
The Gean and JoAnn DeCesare Family Foundation
G1 Therapeutics, Inc.
Mary Ellen Geisser
Bruce & Ellen Geitman
Genentech
Barbara Gentile Family Trust
Jean-Yves Gerardy
Aaron Gerdes
Larry C. German
Gregg C. Gibson
Clyde & Oda Goldbach
Rev. Abdias Gonzalez, C.O.R.C.
Dick and Caren Gorenberg
GRAIL
The Greater Cincinnati Foundation
Guardant Health
Adrienne Halper
The Hansen Family
Martin E. Harband
Peter Harper
HealthMyne
Shelley Heed
The Herbst Foundation
Jane and Reed Hilliard
Houston Methodist Hospital International Association for the Study of Lung Cancer
Ianssen
Jazz Pharmaceuticals
Bradley & Sharon Katz
Kokua Na Lani
Steve & Arlene Krieger
David Lefkowitz
Hayne and Kit Leland
John Letzelter
Stefano Liotta
Ruth Mathew
Truphti Mathew
John Matthews & Beth Solomon
Ride Hard Breathe Easy
John McCormick
Joan McKay
MD Anderson Cancer Center
Memorial Healthcare System
Memorial Sloan-Kettering Cancer Center
Merck & Co.
MetLife
Fred & Linda Milanovich
Vincent A. Miller, MD
Paul and Jane Millman
Mirati Therapeutics, Inc.
The Cynthia & George Mitchell Foundation
Morgan-Loveland Interiors, LLC
NeuroLogica
Jonathan and Lynn Norton
Novartis
Novocure
John & Sarah O’Connor
Sérgio Oliveira
Oncostryte
Nancy Pape
Joy and Lisa Park
Barbara Parkman
The Patel Family
PeerView Institute for Medical Education
Mike and Melina Petlin
John Pender
Paula C. Perry
Perry Communications Group, Inc.
Fizer
Doug Pinder
Julie Pollitz
Lisa Poulin
Parasol Tahoe Community Foundation
Nancee Pransati
Pura Vida Bracelets
Quality Chain Corp.
Frank & Denise Quattrone Foundation
Regeneron Pharmaceuticals
Barbara Picasso Rex Foundation
Rimini Street
Riverain Technologies
Roche
The Rodgers Family Foundation
The Rogers Foundation
Mr. and Mrs. Frank Rondi
Sanofi Genzyme
MAS Solutions Group, LLC
Evy Schifman
Eric & Ashley Sedman
The Sita Foundation
The Society of Thoracic Surgeons
Christopher Spafford
Nicholas E. Steck

Bill & Paula Steele
John & Junie Sullivan, Jr.
Alan Swenson
Syncopation Foundation
Takeda Pharmaceutical Company
The Todd Thomas Foundation
Thynk Health
Thermo Fisher Scientific
The Todd Thomas Foundation
Daniel and Lynne Trump
Trump, Alotta, Trump & Prescott LLP
David L. Turner
University of California, Davis
Randalph & Eliza Urmston
Van & Eddi Van Auk
Van Aukin Private Foundation
Veracyte
Veran Medical Technologies
The Vineyard House, LLC
W.F. & Marie Button Foundation
Loralee S. West
Page West
Catherine H. Wilks-Melson
Jim & Karen Withrow
Eva Wolfsahn Fund
The WRG Foundation
Marshall Ziock